COGNEX Drug Patent Profile

When do Cognex patents expire, and what generic alternatives are available?

Cognex is a drug marketed by Shionogi Inc and is included in one NDA.

The generic ingredient in COGNEX is tacrine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the tacrine hydrochloride profile page.

Summary for COGNEX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	75
Patent Applications:	4,402
DailyMed Link:	COGNEX at DailyMed

US Patents and Regulatory Information for COGNEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-001	Sep 9, 1993		DISCN	No	No
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-004	Sep 9, 1993		DISCN	No	No
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-002	Sep 9, 1993		DISCN	No	No
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-003	Sep 9, 1993		DISCN	No	No

Expired US Patents for COGNEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-001	Sep 9, 1993	4,631,286
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-003	Sep 9, 1993	4,816,456
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-004	Sep 9, 1993	4,816,456
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-001	Sep 9, 1993	4,816,456
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-003	Sep 9, 1993	4,631,286

International Patents for COGNEX

See the table below for patents covering COGNEX around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	854261
Spain	554569
Australia	8070787
New Zealand	213932	9-AMINO-1,2,3,4-TETRAHYDROACRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH
South Korea	900007624

Supplementary Protection Certificates for COGNEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0328535	96C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209

Market Dynamics and Financial Trajectory for COGNEX

Last updated: March 22, 2026

What is COGNEX and its market positioning?

Cognex Corporation is a leading provider of machine vision systems, software, and sensors used in manufacturing and logistics automation. Its product portfolio includes industrial barcode readers, vision sensors, and vision systems aimed at quality inspection, identification, and guidance applications.

Core Industries and Application Areas

• Electronics manufacturing
• Automotive assembly
• Food and beverage processing
• Logistics and parcel handling
• Pharmaceutical packaging

Market Share and Competitors

Cognex holds approximately 15-20% of the global machine vision market share, competing with Basler, Keyence, and National Instruments. Its market share varies across regions, with North America accounting for nearly 45% of revenue, Europe 35%, and Asia-Pacific 20% (Q4 2022 report [1]).

What are the key market drivers?

Industry Automation Growth

The increased deployment of automation in manufacturing to boost efficiency is accelerating demand for machine vision systems. Governments and corporations invest heavily in Industry 4.0 initiatives, expanding the addressable market for Cognex.

E-commerce and Logistics Expansion

Growth in logistics and parcel handling, driven by e-commerce, amplifies demand for barcode readers and vision sensors for sorting and tracking. Amazon, Alibaba, and other logistics players implement Cognex technologies to optimize operations.

Quality Control and Traceability

Stringent quality standards, especially in pharmaceuticals and food sectors, require advanced inspection systems. Cognex's inspection solutions help meet regulatory compliance and reduce product recalls.

Technological Advances

Development in deep learning, AI integration, and industrial IoT enhances the capabilities of Cognex systems, positioning it favorably for future market share expansion.

How does the financial trajectory look?

Revenue Growth

Cognex reported revenues of $979 million in fiscal year 2022, representing a 10% increase over 2021. Growth was driven predominantly by increased demand in the electronics and logistics sectors.

Year	Revenue (USD Million)	Growth Rate
2020	890	-
2021	888	0.2%
2022	979	10.1%

Profitability

Gross margin stabilized around 65% in 2022, with net income of $173 million, up 12% from 2021. Operational expenses rose 8%, primarily due to R&D investments.

Free Cash Flow

Cognex generated $120 million in free cash flow during 2022. The company maintains a solid balance sheet with cash and cash equivalents totaling $400 million and no long-term debt.

Investment and R&D Trends

R&D expenditure increased to $65 million in 2022, about 6.6% of revenue, focusing on AI-powered vision systems and deep learning capabilities.

Shareholder Returns

Cognex returned approximately $80 million to shareholders through dividends and share repurchases in 2022. The company’s dividend payout ratio is roughly 35%, with a quarterly dividend of $0.07 per share.

What are the risks and opportunities?

Risks

• Supply chain disruptions affecting component availability.
• Competitive pressures from firms investing heavily in AI and machine vision.
• Regulatory changes impacting export markets, especially in Europe and Asia.
• Technological obsolescence due to rapid innovation cycles.

Opportunities

• Expansion into emerging markets with rising manufacturing automation.
• Growth in the food, beverage, and pharmaceutical sectors needing inspection solutions.
• Adoption of AI and IoT, allowing for smarter, more integrated vision systems.
• Strategic partnerships and acquisitions to diversify product offerings.

How will the market evolve?

The machine vision market is projected to grow at a CAGR of around 9% from 2023 to 2030, reaching approximately $10 billion globally [2]. Cognex aims to capture a significant portion of this growth through technological innovation and geographic expansion.

Key Takeaways

• Cognex operates in a growing industry driven by automation, logistics, and quality requirements.
• Revenue increased by 10% in 2022, with stable profitability.
• The company invests heavily in R&D to maintain technological leadership.
• Market expansion hinges on emerging markets and sectors like pharmaceuticals.
• Risks include supply chain issues and competitive innovation pushes.

FAQs

Q1. How is Cognex positioned against competitors?
Cognex has approximately 15-20% share of the global machine vision market and is recognized for reliable industrial inspection solutions. Its emphasis on AI integration provides a technological edge.

Q2. What is the outlook for revenue growth?
Revenue is expected to grow at a CAGR of 8-10% through 2025, driven by expansion in automation and logistics sectors.

Q3. What are main growth markets for Cognex?
Emerging markets in Asia-Pacific, pharmaceutical inspection, and AI-enabled vision systems in manufacturing present significant opportunities.

Q4. How vulnerable is Cognex to supply chain disruptions?
Supply chain issues could impact component availability, causing production delays and revenue shortfalls, especially in semiconductor supplies.

Q5. What strategic moves could enhance Cognex’s market position?
Partnerships in AI and IoT, acquisition of niche competitors, and expansion into new sectors like renewable energy and medical devices.

References

[1] Cognex Corporation. (2022). Annual Report.
[2] MarketsandMarkets. (2022). Machine Vision Market by Component, Application, and Region.